Trials / Terminated
TerminatedNCT02676310
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-01-01
- Completion
- 2017-03-01
- First posted
- 2016-02-08
- Last updated
- 2017-03-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02676310. Inclusion in this directory is not an endorsement.